Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of remibrutinib in adults with moderate to severe hidradenitis suppurativa
2025-523259-72-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, double-blind trial of remibrutinib in hidradenitis suppurativa (HS) (2 arms), sponsored by Novartis. Primary endpoint: Occurrence of treatment-emergent adverse events. Planned start Oct 2026; status: authorised.
02
Drugs
remibrutinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2025-523259-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523259-72-00.